Genome Mining ofSalinisporaUncovers a Repertoire of Secondary Metabolites and Carbohydrate-Active Enzymes

Natural products derived from microorganisms are a significant part of the pharmaceutical industry’s arsenal today. These efforts have increasingly centred on marine microbes, which have produced a variety of intriguing novel chemicals. Marine-derived strains are likely candidates for natural product discovery since actinomycetes are a significant source of microbially produced natural compounds. The availability of microbial genome sequencing has revealed a number of natural products (NPs) that have not yet been thoroughly investigated. The genome mining potential of the genus Salinispora , which has potential for the production of secondary metabolites of clinical importance, remains unexplored. In this study, we have demonstrated a thorough comprehension of the genetic characteristics, biosynthetic gene clusters (BGCs), and genetic clusters for carbohydrate-active enzymes found in the Salinispora genomes. In our analysis, we have identified 686 BGCs, among which 3.79% are identical to the BGCs that produce ketomemicin B3/ketomemicin B4, salinilactam, lymphostin/neolymphostinol B/lymphostinol/neolymphostin B, benzastatin, and thiolactomycin. We have found 19.5% of the BGCs, which are only present in the genomes of Salinispora and may open the door to the development of novel drugs. We have also found a total of 3604 genes in 62 various categories of the six major carbohydrate-active enzymes. The development of new-generation bioactive compounds that are significant for biotechnology relies heavily on the scientific insights provided by genome mining in this genus.